This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Analysis of Genetic Factors Which May Influence the Course of HIV Infection

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Deborah Rund, Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00159068
First received: September 9, 2005
Last updated: August 9, 2017
Last verified: August 2017
  Purpose
Patients with HIV an have a variable course of their infection. We are trying to identify factors which worsen or ameliorate the course of the disease. Such factors may be related to metabolism (breakdown) of drugs or to iron handling by the body.

Condition
HIV Infection

Study Type: Observational
Study Design: Observational Model: Other
Time Perspective: Prospective
Official Title: Genetic Influences on the Course and Response to Treatment of HIV: Contribution of Polymorphisms in Drug Metabolism and Disposition Genes and Haptoglobin Polymorphisms

Resource links provided by NLM:


Further study details as provided by Deborah Rund, Hadassah Medical Organization:

Biospecimen Retention:   Samples With DNA
DNA isolated from peripheral blood.

Enrollment: 100
Study Start Date: February 2004
Study Completion Date: April 2011
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Detailed Description:
Patients with HIV can have a variable course and the disease may be influenced by polymorphisms in drug metabolism and disposition genes such as MDR1 and CYP3A4. In addition, reports have linked changes in the course of the disease with iron status, with high iron being detrimental. We will study polymorphisms in these genes and correlate with clinical course in HIV patients and also with phenotype of drug resistance and disease parameters (such as CD4 counts and opportunistic infections).
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with HIV attending the HIV clinic at Hadassah colden globes.
Criteria

Inclusion Criteria:

  • diagnosis of HIV

Exclusion Criteria:

  • under 18 years of age
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00159068

Locations
Israel
Hadassah Medical Organization
Jerusalem, Israel, IL91120
Sponsors and Collaborators
Deborah Rund
Investigators
Principal Investigator: Deborah Rund, MD Hadassah Medical Organization
  More Information

Publications:
Responsible Party: Deborah Rund, Senior Hematologist, Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT00159068     History of Changes
Other Study ID Numbers: 391200-HMO-CTIL
Study First Received: September 9, 2005
Last Updated: August 9, 2017

Additional relevant MeSH terms:
Infection
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases

ClinicalTrials.gov processed this record on September 19, 2017